*HIV Research Branch and the Office of Clinical Site Oversight at the Division of AIDS, National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD; †PRA International, Raleigh, NC; and ‡Office of HIV/AIDS Network Coordination, Fred Hutchinson Cancer Research Center, Seattle, WA.
J Acquir Immune Defic Syndr. 2014 Jan 1;65 Suppl 1(0 1):S40-3. doi: 10.1097/QAI.0000000000000041.
Clinical trial oversight is a critical element that ensures the protection of research participants and integrity of the data collected. The trial sponsor, a local Institutional Review Board, and independent monitoring committees all contribute with complementary but overlapping responsibilities. Consistency among these groups is essential for the smooth conduct of a clinical trial but may be challenging in resource-limited settings (RLS). Capacity building and training for RLS may improve clinical trials oversight and ultimately medical management. In this article, we review the components necessary for optimal clinical trial oversight and the issues that arise in the RLS, with some suggested strategies for improvement.
临床试验监督是确保研究参与者得到保护和所收集数据完整性的关键要素。试验赞助商、当地机构审查委员会和独立监测委员会都承担着互补但重叠的责任。这些团体之间的一致性对于临床试验的顺利进行至关重要,但在资源有限的环境中(RLS)可能具有挑战性。为 RLS 进行能力建设和培训可能会改善临床试验监督,并最终改善医疗管理。在本文中,我们回顾了最佳临床试验监督所需的组成部分,以及在 RLS 中出现的问题,并提出了一些改进策略。